Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brexanolone - Sage Therapeutics

Drug Profile

Brexanolone - Sage Therapeutics

Alternative Names: Allopregnanolone/sulfobutylether‐beta‐cyclodextrin; brexanolone IV; SAGE-547; SGE-102; ZULRESSO

Latest Information Update: 09 May 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California, Davis
  • Developer SAGE Therapeutics
  • Class Antidepressants; Antiepileptic drugs; Small molecules; Steroids
  • Mechanism of Action GABA A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Status epilepticus
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Postnatal depression
  • Discontinued Essential tremor; Major depressive disorder; SARS-CoV-2 acute respiratory disease; Status epilepticus

Most Recent Events

  • 09 May 2022 Sage Therapeutics has patent protection for Brexanolone in USA
  • 11 Feb 2022 Discontinued - Phase-III for SARS-COV-2 acute respiratory disease in USA (IV) (SAGE Therapeutics pipeline, February 2022)
  • 31 Dec 2021 SAGE Therapeutics has patents pending for brexanolone in USA and other countries
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top